Early Results from Multiple Myeloma Clinical Trial Prove Cancer Drug Combination Provides Longer Response and Potential Benefit in Disease-Free Survival
October 02, 2024Patients with multiple myeloma, a type of cancer in their white blood cells, have a significantly longer disease-free period and likely long-term survival if they are treated with the monoclonal antibody drug daratumumab along with the standard therapy drug lenalidomide compared to the standard therapy alone.